BOSTON--(BUSINESS WIRE)--EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, announced today the pricing of an underwritten public offering of 9.6 million shares of its common stock, offered at a price to the public of $5.00 per share. Net proceeds to EPIRUS from this offering are expected to be approximately $44.2 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. EPIRUS intends to use the net proceeds from the offering to progress its global BOW015 clinical program and to advance the development of its other product candidates, as well as for general corporate and working capital purposes.
Help employers find you! Check out all the jobs and post your resume.
